Literature DB >> 10502570

Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy of a 0.1% (w/v) sodium hyaluronate solution (Fermavisc) in the treatment of dry eye syndrome.

P I Condon1, C G McEwen, M Wright, G Mackintosh, R J Prescott, C McDonald.   

Abstract

BACKGROUND/AIMS: Hyaluronan (sodium hyaluronate) has been shown to confer objective and subjective improvement in patients with dry eye syndrome. This study compared the efficacy and safety of a 0.1% solution of hyaluronan with 0.9% saline, when administered topically to the eye, in the treatment of symptoms of severe dry eye syndrome.
METHODS: A randomised, double blind, crossover clinical trial in which subjects were randomised to receive either hyaluronan or saline, applied as one or two drops to the eye, three or four times a day or as required. After 28 days' treatment, subjects crossed over to the other study medication for a further 28 days' treatment.
RESULTS: 70 subjects were included in the analyses of efficacy and significant improvements in Schirmer's score (p=0.0006) and rose bengal staining score (p=0.0001) were observed during treatment with hyaluronan. In a subjective assessment of the effectiveness of two treatments, a majority of subjects felt that hyaluronan was more effective than saline in alleviating the symptoms of burning and grittiness (p<0.001). No adverse events attributable to hyaluronan treatment were reported.
CONCLUSION: The study demonstrates a clear benefit of hyaluronan over saline, in both subjective and objective assessments of dry eye syndrome. Hyaluronan was shown to be well tolerated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10502570      PMCID: PMC1722832          DOI: 10.1136/bjo.83.10.1121

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  Decrease in corneal sensitivity and change in tear function in dry eye.

Authors:  K P Xu; Y Yagi; K Tsubota
Journal:  Cornea       Date:  1996-05       Impact factor: 2.651

2.  The effect of sodium hyaluronate on the corneal epithelium. An ultrastructural study.

Authors:  Y S Wysenbeek; N Loya; I Ben Sira; I Ophir; Y Ben Shaul
Journal:  Invest Ophthalmol Vis Sci       Date:  1988-02       Impact factor: 4.799

3.  Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes.

Authors:  L S Mengher; K S Pandher; A J Bron; C C Davey
Journal:  Br J Ophthalmol       Date:  1986-06       Impact factor: 4.638

4.  Diagnostic tests in the Sicca syndrome.

Authors:  O P van Bijsterveld
Journal:  Arch Ophthalmol       Date:  1969-07

5.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

6.  The use of topical Healon tears in the management of refractory dry-eye syndrome.

Authors:  V P DeLuise; W S Peterson
Journal:  Ann Ophthalmol       Date:  1984-09

7.  Characterization of water retentive properties of hyaluronan.

Authors:  M Nakamura; M Hikida; T Nakano; S Ito; T Hamano; S Kinoshita
Journal:  Cornea       Date:  1993-09       Impact factor: 2.651

8.  Dilute sodium hyaluronate (Healon) in the treatment of ocular surface disorders.

Authors:  J C Stuart; J G Linn
Journal:  Ann Ophthalmol       Date:  1985-03

9.  Sodium hyaluronate eyedrops in the treatment of dry eyes.

Authors:  S Shimmura; M Ono; K Shinozaki; I Toda; E Takamura; Y Mashima; K Tsubota
Journal:  Br J Ophthalmol       Date:  1995-11       Impact factor: 4.638

10.  Sodium hyaluronate eyedrops enhance tear film stability.

Authors:  T Hamano; K Horimoto; M Lee; S Komemushi
Journal:  Jpn J Ophthalmol       Date:  1996       Impact factor: 2.447

View more
  22 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

2.  Performance profile of sodium hyaluronate in patients with lipid tear deficiency: randomised, double-blind, controlled, exploratory study.

Authors:  P Prabhasawat; N Tesavibul; N Kasetsuwan
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

3.  Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis.

Authors:  Françoise Brignole; Pierre-Jean Pisella; Bénédicte Dupas; Vincent Baeyens; Christophe Baudouin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-12-17       Impact factor: 3.117

4.  Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye.

Authors:  Pasquale Aragona; Vincenzo Papa; Antonio Micali; Marcello Santocono; Giovanni Milazzo
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

5.  Optimising tear replacement rheology in canine keratoconjunctivitis sicca.

Authors:  D L Williams
Journal:  Eye (Lond)       Date:  2018-01-05       Impact factor: 3.775

Review 6.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

Review 7.  Treatment of primary Sjögren syndrome.

Authors:  Alain Saraux; Jacques-Olivier Pers; Valérie Devauchelle-Pensec
Journal:  Nat Rev Rheumatol       Date:  2016-07-14       Impact factor: 20.543

8.  Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye.

Authors:  Michael E Johnson; Paul J Murphy; Mike Boulton
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-06-28       Impact factor: 3.117

9.  Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial.

Authors:  Peter A Simmons; Haixia Liu; Cindy Carlisle-Wilcox; Joseph G Vehige
Journal:  Clin Ophthalmol       Date:  2015-04-15

10.  JBP485 promotes tear and mucin secretion in ocular surface epithelia.

Authors:  Takahiro Nakamura; Yuiko Hata; Maho Nagata; Norihiko Yokoi; Shumpei Yamaguchi; Taiichi Kaku; Shigeru Kinoshita
Journal:  Sci Rep       Date:  2015-05-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.